Skip to main content
Livermore
Livermore
ZHEN

Agios Pharmaceuticals, Inc.

AGIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001439222

In the last 90 days, Agios Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 238 institutions reported holding it in 13F filings for Q2 2026, worth $2.45B in total; no superinvestor holds it.

Holders of 5% or more of AGIO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Agios Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of AGIO
HolderLatest formStakeChangeFirst filedLatest filingFiling
Farallon Capital Management, L.L.C.13G/A9.90%5.92M shares–Aug 3, 20261 filingAug 3, 2026SEC
Farallon Capital Partners, L.P.13G/A8.80%5.16M shares−1.10 ppfrom 9.90%Feb 4, 20252 filingsFeb 9, 2026SEC
BlackRock, Inc.13G/A7.80%4.51M shares–Jul 17, 20251 filingJul 17, 2025SEC
State Street Corp13G5.30%3.11M sharesNewFeb 9, 20261 filingFeb 9, 2026SEC
Vanguard Capital Management LLC13G5.27%3.09M sharesNewApr 29, 20261 filingApr 29, 2026SEC
D. E. Shaw & Co, L.P.13G5.10%3.03M sharesNewJul 2, 20261 filingJul 2, 2026SEC
Lynx1 Capital Management LP13G5.10%3.01M sharesNewMay 6, 20261 filingMay 6, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

22 Schedule 13D and 13G filings on Agios Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on AGIO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 3, 20268:30 AM ETFarallon Capital Management, L.L.C.and 28 others13G/A9.90%5.92M shares–Jun 30, 2026SEC
Jul 2, 20264:04 PM ETD. E. Shaw & Co, L.P.and 1 other13G5.10%3.03M sharesNewJun 25, 2026SEC
May 15, 202611:01 AM ETArmistice Capital, LLCand 1 other13G/A4.57%2.72M shares−0.64 ppfrom 5.21%Below 5%Mar 31, 2026SEC
May 6, 20264:21 PM ETLynx1 Capital Management LPand 1 other13G5.10%3.01M sharesNewApr 29, 2026SEC
Apr 29, 20264:38 PM ETVanguard Capital Management LLC13G5.27%3.09M sharesNewMar 31, 2026SEC
Mar 26, 20263:12 PM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
Feb 17, 20269:54 PM ETArmistice Capital, LLCand 1 other13G5.21%3.04M sharesNewDec 31, 2025SEC
Feb 9, 20268:54 AM ETFarallon Capital Partners, L.P.and 30 others13G/A8.80%5.16M shares−1.10 ppfrom 9.90%Dec 31, 2025SEC
Feb 9, 20266:15 AM ETState Street Corp13G5.30%3.11M sharesNewDec 31, 2025SEC
Dec 5, 20255:42 PM ETBellevue Group AGand 1 other13G/A0.00%0 shares−6.10 ppfrom 6.10%Below 5%Nov 19, 2025SEC
Nov 14, 20254:34 PM ETParadigm Biocapital Advisors LPand 3 others13G/A4.90%2.87M shares−0.30 ppfrom 5.20%Below 5%Sep 30, 2025SEC
Aug 28, 20254:31 PM ETParadigm Biocapital Advisors LPand 3 others13G5.20%3.03M sharesNewAug 21, 2025SEC
Jul 17, 20257:44 PM ETBlackRock, Inc.13G/A7.80%4.51M shares–Jun 30, 2025SEC
Jul 7, 20257:32 PM ETBellevue Group AGand 1 other13G6.10%3.52M sharesNewJun 1, 2025SEC
Jun 13, 20252:50 PM ETBB Biotech AGand 1 other13G/A0.00%0 shares−6.20 ppfrom 6.20%Below 5%Jun 1, 2025SEC
Feb 14, 20252:35 PM ETBB Biotech AGand 1 other13G/A6.20%3.52M shares–Dec 31, 2024SEC
Feb 4, 202512:02 PM ETFarallon Capital Partners, L.P.and 29 others13G/A9.90%5.67M shares–Dec 31, 2024SEC
Mar 10, 2021FMR LLC13G/AOld format–––SEC
Feb 12, 2021BB Biotech AG13G/AOld format–––SEC
Feb 10, 2021Vanguard Group Inc13G/AOld format–––SEC
Feb 8, 2021FMR LLC13G/AOld format–––SEC
Feb 3, 2021Wellington Management Group LLP13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Agios Pharmaceuticals, Inc. shares.

No Form 144 notices for Agios Pharmaceuticals, Inc. are on file.